GSK completes $10.6B Nuvalent acquisition

Q: What transaction did GSK (GSK) report in its July 2026 Form 6-K?

GSK reported completion of its acquisition of Nuvalent, Inc., a clinical-stage oncology company. The deal adds three targeted lung cancer assets, including two late-stage candidates under FDA review for specific non-small cell lung cancer populations.

Q: Which oncology assets did GSK (GSK) gain through the Nuvalent acquisition?

GSK gained three lung cancer assets: zidesamtinib (NVL-520) for ROS1-positive NSCLC, neladalkib (NVL-655) for ALK-altered NSCLC, both under FDA review, and NVL-330, a phase I candidate for HER2-altered non-small cell lung cancer.

Q: What regulatory designations do GSK’s new NSCLC drugs from Nuvalent have?

Zidesamtinib and neladalkib have both received FDA Breakthrough Therapy and Orphan Drug Designations. They are under FDA review for ROS1-positive and ALK-altered non-small cell lung cancer, with target decision dates later in 2026, according to GSK.

Q: When does GSK (GSK) expect the new Nuvalent lung cancer drugs to launch?

GSK states that, if approved, zidesamtinib and neladalkib are expected to launch in 2026 with multi-blockbuster potential. These expectations depend on FDA review outcomes and reflect GSK’s view of their commercial opportunity.

Q: How does Nuvalent support GSK’s broader oncology strategy?

GSK explains the deal accelerates its entry into lung cancer and complements its focus on precisely targeted therapies. The assets align with GSK’s oncology ambition to improve quality of life and survival, alongside programmes such as B7-H3 and B7-H4 antibody-drug conjugates.

GSK plc has completed its acquisition of Nuvalent, Inc., a Boston-based clinical-stage biopharmaceutical company developing precisely targeted oncology therapies.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

6-K

Rhea-AI Filing Summary

GSK plc has completed its acquisition of Nuvalent, Inc., a Boston-based clinical-stage biopharmaceutical company developing precisely targeted oncology therapies. The deal adds three lung cancer assets to GSK’s portfolio, strengthening its planned expansion from blood and women’s cancers into lung and other solid tumours.

The transaction was executed via a tender offer for all of Nuvalent’s outstanding shares, with an aggregate equity value of $10.6 billion (£8.0 billion). Net of cash acquired, GSK’s aggregate investment is approximately $9.4 billion (£7.1 billion). The acquisition includes zidesamtinib (NVL-520) and neladalkib (NVL-655), both under FDA review for specific forms of non-small cell lung cancer and holding Breakthrough Therapy and Orphan Drug Designations, which GSK states are expected, if approved, to launch in 2026 with multi-blockbuster potential. It also brings NVL-330, in phase I for HER2-altered non-small cell lung cancer.

Key Figures

Aggregate equity value: $10.6 billion Net investment: $9.4 billion Assets acquired: 3 lung cancer assets +1 more

4 metrics

Aggregate equity value $10.6 billion Aggregate equity value of the Nuvalent transaction

Net investment $9.4 billion GSK’s aggregate investment net of cash acquired in the Nuvalent deal

Assets acquired 3 lung cancer assets Number of lung cancer assets added to GSK’s oncology portfolio

Breakthrough Therapy assets 2 drugs Zidesamtinib and neladalkib have FDA Breakthrough Therapy Designations

Key Terms

Breakthrough Therapy, Orphan Drug Designations, non-small cell lung cancer, antibody-drug conjugates, +1 more

5 terms

Breakthrough Therapy medical

"Both have received FDA Breakthrough Therapy and Orphan Drug Designations"

A breakthrough therapy is a regulatory designation granted to an experimental drug or treatment when early clinical evidence indicates it could offer a substantial improvement over existing options for a serious or life‑threatening condition. For investors it matters because the label brings faster, more intensive interaction with regulators and can shorten development and review time—like a VIP fast‑track toward potential approval, reducing time and risk before a product can reach the market.

Orphan Drug Designations medical

"Both have received FDA Breakthrough Therapy and Orphan Drug Designations"

A regulatory status granted to medicines that treat rare diseases, giving developers special incentives and protections — for example, reduced fees, tax benefits, and a period of exclusive marketing once approved. Think of it as a government “boost” that lowers development costs and shields a product from direct competition for a time; investors watch for it because it can raise a drug’s commercial value and reduce the financial risk of bringing a treatment for a small patient group to market.

non-small cell lung cancer medical

"under FDA review for ROS1-positive and ALK-altered non-small cell lung cancer"

A broad category of lung tumors that grow from the cells lining the airways and make up the majority of lung cancer cases; it includes several subtypes that behave and respond to treatment differently, like different models of the same car family. It matters to investors because its large patient population and variety of treatment options — surgery, traditional chemo, targeted drugs and immunotherapies — create major markets where clinical trial results, drug approvals or changing treatment guidelines can quickly affect a company’s revenue and stock value.

antibody-drug conjugates medical

"priority programmes such as antibody-drug conjugates Ris-Rez targeting B7-H3"

A class of targeted cancer medicines that combine a lab-made antibody (which finds and sticks to specific markers on tumor cells) with a powerful cell-killing drug linked together so the toxic payload is delivered directly to the tumor. Think of it like a guided missile that reduces collateral damage compared with traditional chemotherapy; for investors, success or failure of these drugs drives clinical, regulatory and commercial value and can sharply affect a biotech company’s prospects and stock price.

tender offer financial

"GSK completed a tender offer to acquire all of Nuvalent's outstanding shares"

A tender offer is a proposal made by a person or company to buy shares from existing shareholders at a set price, usually higher than the current market value, within a specific time frame. It matters to investors because it can lead to a change in ownership or control of a company, and shareholders must decide whether to sell their shares at the offered price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did GSK (GSK) report in its July 2026 Form 6-K?

GSK reported completion of its acquisition of Nuvalent, Inc., a clinical-stage oncology company. The deal adds three targeted lung cancer assets, including two late-stage candidates under FDA review for specific non-small cell lung cancer populations.

How much did GSK (GSK) invest to acquire Nuvalent?

GSK states the Nuvalent transaction has an aggregate equity value of $10.6 billion (£8.0 billion). Net of cash acquired, GSK’s aggregate investment is approximately $9.4 billion (£7.1 billion), reflecting the effective cash outlay associated with the acquisition.

Which oncology assets did GSK (GSK) gain through the Nuvalent acquisition?

GSK gained three lung cancer assets: zidesamtinib (NVL-520) for ROS1-positive NSCLC, neladalkib (NVL-655) for ALK-altered NSCLC, both under FDA review, and NVL-330, a phase I candidate for HER2-altered non-small cell lung cancer.

What regulatory designations do GSK’s new NSCLC drugs from Nuvalent have?

Zidesamtinib and neladalkib have both received FDA Breakthrough Therapy and Orphan Drug Designations. They are under FDA review for ROS1-positive and ALK-altered non-small cell lung cancer, with target decision dates later in 2026, according to GSK.

When does GSK (GSK) expect the new Nuvalent lung cancer drugs to launch?

GSK states that, if approved, zidesamtinib and neladalkib are expected to launch in 2026 with multi-blockbuster potential. These expectations depend on FDA review outcomes and reflect GSK’s view of their commercial opportunity.

How does Nuvalent support GSK’s broader oncology strategy?

GSK explains the deal accelerates its entry into lung cancer and complements its focus on precisely targeted therapies. The assets align with GSK’s oncology ambition to improve quality of life and survival, alongside programmes such as B7-H3 and B7-H4 antibody-drug conjugates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 07/15/2026 - 09:11 AM EDT

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 15 July 2026, London UK

GSK completes acquisition of Nuvalent, Inc.

GSK plc (LSE/NYSE: GSK) today announced completion of its acquisition of Nuvalent, Inc.[1], a Boston-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies.

The acquisition adds three lung cancer assets to GSK's oncology portfolio. Zidesamtinib (NVL-520) and neladalkib (NVL-655) are considered potential best-in-class assets, based on clinical data, and are under FDA review for ROS1-positive and ALK-altered non-small cell lung cancer (NSCLC) with target decision dates later this year. Both have received FDA Breakthrough Therapy and Orphan Drug Designations. If approved, they are expected to launch in 2026 with multi-blockbuster potential. The acquisition also includes NVL-330 in phase I development for HER2-altered NSCLC.

Luke Miels, Chief Executive Officer, GSK, said: "Today's deal completion accelerates our entry into lung cancer with zidesamtinib and neladalkib and a platform for rapid expansion with Ris-Rez, our B7-H3 targeted ADC in phase III development. There is a clear need for these medicines in defined patient populations, consistent with our approach of acquiring validated assets that aim to improve standard of care."

Financial considerations

Under the terms of the agreement, GSK completed a tender offer to acquire all of Nuvalent's outstanding shares. The aggregate equity value of the transaction is approximately $10.6 billion (£8.0 billion). Net of cash acquired, GSK's aggregate investment is approximately $9.4 billion (£7.1 billion).

About NSCLC

NSCLC is the most common form of lung cancer and is often characterised by specific genetic alterations, such as those in ALK, ROS1, or HER2. It can often metastasise (i.e. spread) to the central nervous system. It primarily affects working-age individuals. Current treatments are associated with mutation resistance and side effects, including metabolic and neurologic events, that can adversely impact patients' quality of life.

About Nuvalent

Nuvalent (NASDAQ: NUVL) is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, Nuvalent develops innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery stage research programs.

GSK in oncology

Our ambition in oncology is to help increase overall quality of life, maximise survival and change the course of disease, expanding from our current focus on blood and women's cancers into lung and gastrointestinal cancers, as well as other solid tumours. This includes accelerating priority programmes such as antibody-drug conjugates Ris-Rez targeting B7-H3 and Mo-Rez targeting B7-H4, and velzatinib, a highly selective KIT tyrosine kinase inhibitor.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

GSK enquiries
Media:	Tim Foley	+44 (0) 20 8047 5502	(London)
	Sarah Clements	+44 (0) 20 8047 5502	(London)
	Kathleen Quinn	+1 202 603 5003	(Washington DC)
	Alison Hunt	+1 540 742 3391	(Washington DC)

Investor Relations:	Constantin Fest	+44 (0) 7831 826525	(London)
	James Dodwell	+44 (0) 20 8047 2406	(London)
	Mick Readey	+44 (0) 7990 339653	(London)
	Steph Mountifield	+44 (0) 7796 707505	(London)
	Sam Piper	+44 (0) 7824 525779	(London)
	Joanna Tuplin	+44 (0) 7788 351650	(London)
	Dan Smith	+44 (0) 7823 523885	(London)
	Jeff McLaughlin	+1 215 751 7002	(Philadelphia)
	Frannie DeFranco	+1 215 751 3126	(Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025, and GSK's Q1 Results for 2026.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

[1] GSK press release issued 9 June. GSK enters agreement to acquire Nuvalent, Inc. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-enters-agreement-to-acquire-nuvalent-inc/.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

	GSK plc
	(Registrant)

Date: July 15, 2026

	By:/s/ VICTORIA WHYTE --------------------------

	Victoria Whyte
	Authorised Signatory for and on
	behalf of GSK plc

Source: View Original Filing on SEC EDGAR